The papillomavirus E5 proteins are short, hydrophobic transforming proteins. The transmembrane E5 protein encoded by bovine papillomavirus transforms cells by activating the platelet-derived growth factor b receptor tyrosine kinase in a ligand-independent fashion. The bovine papillomavirus E5 protein forms a stable complex with the receptor, thereby inducing receptor dimerization and activation, trans-phosphorylation, and recruitment of cellular signaling proteins to the receptor. The E5 proteins of the human papillomaviruses also appear to aect the activity of growth factor receptors and their signaling pathways. The interaction of papillomavirus E5 proteins with a subunit of the vacuolar ATPase may also contribute to transformation. Further analysis of these unique mechanisms of viral transformation will yield new insight into the regulation of growth factor receptor activity and cellular signal transduction pathways. Oncogene (2001) 20, 7866 ± 7873.
Introduction
Studies of the mechanisms by which viruses transform cells have provided important insights into many aspects of cell function. DNA tumor viruses often induce transformation by neutralizing cellular tumor suppressor proteins such as p53 and p105
Rb . Other tumor virus transforming proteins activate cellular growth stimulatory pathways, a mechanism we have named`Virocrine transformation . This review focuses on unusual viral transforming proteins in this class, the E5 proteins encoded by the papillomaviruses. The E5 protein of bovine papillomavirus type 1 (BPV) induces transformation by binding to and activating the platelet-derived growth factor (PDGF) b receptor, and the E5 proteins encoded by the human papillomaviruses may use a related mechanism to transform cells. Other viral transforming proteins that employ similar strategies are polyomavirus middle T antigen, which mimics an activated receptor tyrosine kinase, Epstein-Barr virus LMP1, which mimics an activated tumor necrosis factor receptor, and Friend leukemia virus gp55, which activates the erythropoietin receptor .
Bovine papillomavirus E5 protein
The BPV E5 protein is a very hydrophobic 44-amino acid type II transmembrane protein that can induce morphologic and tumorigenic transformation of rodent and human ®broblasts (Schlegel et al., 1986; . It is localized largely to the membranes of the endoplasmic reticulum and Golgi apparatus of transformed cells and exists as a dimer of two identical subunits linked by disul®de bonds involving cysteine residues in the carboxyl-terminal third of the protein (Burkhardt et al., 1989; Horwitz et al., 1988; Schlegel et al., 1986) . The BPV E5 protein does not have intrinsic enzymatic activity but rather induces transformation by modulating the activity of cellular membrane proteins that regulate cell growth. Two ®ndings suggested that growth factor receptors were targets of the BPV E5 protein. First, the E5 gene displayed increased focus forming activity in NIH3T3 cells when it was co-transfected with genes encoding receptor tyrosine kinases (RTKs) (Martin et al., 1989) . Second, acute expression of the BPV E5 protein, like treatment with serum or puri®ed growth factors, induced quiescent ®broblasts to commence DNA synthesis (Settleman et al., 1989) .
The role of the PDGF b receptor in transformation by the BPV E5 protein Expression of the BPV E5 protein induces constitutive activation of the PDGF b receptor in transformed cells (Petti et al., 1991) , but it does not directly activate other receptors, including the closely related PDGF a receptor or the EGF receptor Petti and DiMaio, 1994) . The PDGF b receptor activated by the BPV E5 protein shares several properties with the receptor activated by PDGF: it contains elevated levels of phosphotyrosine, displays increased in vitro tyrosine kinase activity, and is constitutively associated with various SH2 domaincontaining cellular proteins that play essential roles in the response to PDGF (Figure 1) (Cohen et al., 1993a; Drummond-Barbosa et al., 1995; Goldstein et al., 1994; Lai et al., 1998; Nilson and DiMaio, 1993; Petti and DiMaio, 1994; Petti et al., 1991) . Furthermore, like PDGF, the BPV E5 protein induces dimerization and trans-phosphorylation of the receptor . Expression of the BPV E5 protein can also induce PDGF b receptor down-regulation (Nilson et al., 1995) , another measure of receptor activation. This eect is particularly striking in human ®broblasts at high cell density, where it may be mediated by a secreted factor (Petti and Ray, 2000) .
Gene transfer experiments in cell lines lacking endogenous PDGF b receptor demonstrated that activation of the PDGF b receptor is required for cell transformation by the BPV E5 protein (DrummondBarbosa et al., 1995; Goldstein et al., 1994; Nilson and DiMaio, 1993) . Cells lacking the PDGF b receptor are not susceptible to E5-induced transformation. However, co-expression of the BPV E5 protein and the PDGF b receptor causes receptor activation and transformation and provides an anti-apoptotic signal in the face of growth factor deprivation. Other receptor tyrosine kinases do not allow E5 transformation in this assay . E5-induced growth factor-independent proliferation requires the expression of a catalytically active PDGF b receptor (DrummondBarbosa et al., 1995) , indicating that the receptor tyrosine kinase has to activate the receptor signaling cascade to deliver a proliferative signal. In separate lines of experiments, treatment of E5-transformed mouse ®broblasts with a speci®c inhibitor of the PDGF receptor tyrosine kinase leads to the reversal of the transformed phenotype (Klein et al., , 1999 , and C127 cell variants impaired in their response to PDGF are also relatively resistant to transformation by the BPV E5 protein (Riese and DiMaio, 1995) . Finally, we have observed an excellent correlation between the ability of various E5 mutants to bind to and activate the PDGF b receptor and to transform cells (Klein et al., , 1999 Nilson et al., 1995) .
Thus, there is compelling evidence that activation of the PDGF b receptor plays a central role in E5-induced transformation, as it does in transformation by the v-sis gene product, a homologue of PDGF.
It has been reported that certain E5 mutants transform cells or aect cellular metabolism without binding to or activating the PDGF b receptor, suggesting that these mutants utilize alternative, PDGF b receptor-independent mechanisms to transform cells (Schapiro et al., 2000; Sparkowski et al., 1996; Suprynowicz et al., 2000; Vali et al., 2001) . However, more recent results from our laboratory indicate that at least some of these mutants interact productively with the PDGF b receptor (CC Lai and D DiMaio, unpublished results). It is likely that these discrepancies result at least in part from methodological dierences. However, there are E5 point mutants and chimeric E5-like proteins that undergo complex formation with the PDGF b receptor and cause receptor tyrosine phosphorylation, but do not transform cells (Mattoon et al., 2001; Nilson et al., 1995) . It is possible that these E5 mutants cause aberrant receptor autophosphorylation that is unable to initiate mitogenic signaling.
Mechanism of PDGF b receptor activation by the BPV E5 protein
The BPV E5 protein and the activated PDGF b receptor form a stable complex in cells (Goldstein et al., 1992a; DiMaio, 1992, 1994) , suggesting that the BPV E5 protein induces activation of the PDGF b receptor by binding to it. However, unlike PDGF, which binds to the extracellular domain of the receptor, the BPV E5 protein interacts with transmembrane and juxtamembrane domains of the PDGF b receptor (Cohen et al., 1993a; Drummond-Barbosa et al., 1995; Goldstein et al., 1992a; Petti et al., 1997; Staebler et al., 1995) . Indeed, the BPV E5 protein can bind to a short fragment of the PDGF b receptor consisting of the transmembrane domain and a few anking amino acids (L Petti and J Schaefer (Albany Medical College)), indicating that all the sequence information required for stable complex formation is present in this fragment. Furthermore, the BPV E5 protein can activate receptor mutants lacking the extracellular ligand binding domain, demonstrating that E5-induced activation of the PDGF b receptor and cell transformation is ligand-independent (Drummond- Barbosa et al., 1995) .
Both PDGF and the BPV E5 protein induce dimerization of the PDGF b receptor and transautophosphorylation of multiple tyrosine residues in the cytoplasmic domains of the two receptor subunits in the dimer . Trans-phosphorylation initiates signaling by the PDGF b receptor by augmenting receptor tyrosine kinase activity and by generating binding sites for SH2 domain-containing signaling proteins (Drummond-Barbosa et al., 1995; Lai et al., 2000; Petti et al., 1991) . In E5-transformed cells, a signal transduction complex consisting of the BPV E5 protein, activated PDGF b receptor, and associated signaling molecules can be detected and physically separated from inactive PDGF b receptor (Lai et al., 2000) .
On the basis of extensive mutational analysis, we proposed that BPV E5/PDGF b receptor complex formation requires an electrostatic bond between a juxtamembrane lysine in the PDGF b receptor and aspartic acid 33 of the BPV E5 protein and a hydrogen-bond between a transmembrane threonine in the receptor and glutamine 17 of the BPV E5 protein (Figure 2 ) (Horwitz et al., 1988 Klein et al., 1998 Klein et al., , 1999 Kulke et al., 1992) . In this model, the type II E5 protein is in the opposite orientation to the type I PDGF b receptor. Mutational studies carried out by the Schlegel and Donaghue laboratories also indicate that glutamine 17 and aspartic acid 33 are important in transformation (Meyer et al., 1994; Sparkowski et al., 1996) . The requirement for these interactions may also explain the inability of the BPV E5 protein to bind to and activate the PDGF a receptor Petti and DiMaio, 1994; Staebler et al., 1995) , which lacks the essential threonine and the lysine. Complex formation also requires dimerization of the E5 protein (Mattoon et al., 2001; Nilson et al., 1995) , and glutamine 17 plays a role in stabilizing the E5 dimer Kulke et al., 1992) .
Biophysical and computational studies indicated that E5 dimers exist in membranes as paired transmembrane a-helices organized as symmetric, parallel, left-handed coiled coils . Molecular modeling identi®ed a potential low energy structure of the E5 dimer in which the aspartic acids point away from the dimer interface so that they are in position to form salt bridges with the essential lysines on the PDGF b receptor molecules and the glutamines are able to form hydrogen bonds across the E5 dimer interface, as well as with the PDGF b receptor (Figure 2) . Such interactions involving the glutamines are also consistent with mutational analysis and the results of solid-state NMR experiments Nilson et al., 1995) (Steven Smith, State University of New York, Stony Brook). In a genetic approach to determine the structure of the active E5 dimer, we used a heterologous dimerization domain to force the E5 monomers to adopt various orientations relative to one another within the dimer (Mattoon et al., 2001) . Analysis of the resulting E5 chimeras revealed that the orientation identi®ed by the computational and NMR analysis is the only one that displayed signi®cant transforming activity.
We have proposed that each dimer of the BPV E5 protein contains binding sites for two molecules of the PDGF b receptor, thus explaining how the E5 protein induces dimerization of the receptor (Surti et al., Mattoon 1998) . Receptor dimerization brings the kinase domains of two receptors into proximity so that they can carry out trans-phosphorylation ). The precise interactions responsible for E5/PDGF receptor complex formation are a matter of controversy. As noted above, mutational analysis suggests that lysine/aspartic acid and threonine/glutamine interactions are important. On the basis of mutational analysis, molecular modeling, analysis of the chimeric E5 proteins, and NMR studies, we proposed that each PDGF b receptor molecule interacts with the glutamine on one E5 monomer and the aspartic acid on the other (Figure 2 ) (Klein et al., , 1999 Mattoon et al., 2001; Surti et al., 1998) . Thus, the E5 protein has to dimerize in order to generate intact binding sites for the PDGF b receptor, a model consistent with the ®nding that dimerization-defective E5 mutants are also defective for inducing receptor activation and transformation.
On the basis of their analysis of alanine scanning mutations in the BPV E5 protein, Schlegel and colleagues proposed that each E5 monomer had an independent binding site for the PDGF b receptor, but the binding site was accessible only following E5 dimerization (Adduci and Schlegel, 1999) . The model further proposed that some E5 mutants form tetramers that could not bind to or activate the PDGF b receptor but were still able to transform cells by an unknown mechanism. It is clear that additional studies are required to de®ne the molecular interactions required for BPV E5/PDGF b receptor complex formation and receptor activation.
The vacuolar H + -ATPase as a target of the BPV E5 protein
The BPV E5 protein also binds to the 16 kDa transmembrane subunit of the vacuolar H + -ATPase (V-ATPase) (Goldstein et al., 1991 (Goldstein et al., , 1992c ). This enzyme is responsible for controlling the pH of the Golgi apparatus and other intracellular organelles, and it may be involved in gap junction function. As is the case for complex formation between the BPV E5 protein and the PDGF b receptor, association between the ATPase subunit and the E5 protein appears to be mediated largely by transmembrane interactions (Andresson et al., 1995; Goldstein et al., 1992a; Goldstein et al., 1992b) . A ternary complex containing the BPV E5 protein, the PDGF b receptor, and the V-ATPase subunit has been detected in cells engineered to overexpress these three proteins (Goldstein et al., 1992a) . Acidi®cation of the Golgi apparatus is impaired in cells transformed by the BPV E5 protein, and it has been proposed that the BPV E5 protein directly inhibits V-ATPase activity (Schapiro et al., 2000; Suprynowicz et al., 2000) . Because many important growth regulatory proteins, including the PDGF b receptor, pass through the Golgi apparatus en route to their ®nal destination in the cell, the ability of the BPV E5 protein to perturb the pH of intracellular organelles may in¯uence the activity of these proteins and contribute to transformation. The BPV E5 protein also binds to a-adaptin, another cellular protein that aects the metabolism of growth factor receptors (Cohen et al., 1993b) . However, the role of these interactions in cell transformation is unclear because it has not been possible to carry out the sort of gene transfer or pharmacological inhibitor studies that established the role of the PDGF b receptor in E5-mediated transformation.
In bovine warts, the BPV E5 protein is expressed in epidermal keratinocytes as well as in dermal ®broblasts (Bohl et al., 2001; Burnett et al., 1992) . Moreover, the BPV E5 protein can cause tumorigenic transformation of established murine keratinocytes (Leptak et al., 1991) . Since keratinocytes do not normally express PDGF receptor, these results suggest that transformation of these cells may be mediated by a dierent cellular target, possibly the V-ATPase. Alternatively, it is possible that the PDGF b receptor is expressed at a low level in these epithelial cells and mediates transformation in this setting as well.
HPV E5 transforming proteins
The E5 proteins encoded by the human papillomaviruses display weak transforming activity. The HPV E5 proteins are about 90 amino acids in length, but other than their overall hydrophobic sequence they do not share signi®cant sequence homology with the BPV E5 protein. The HPV16 and HPV6 E5 proteins localize largely to intracellular membranes including the Golgi apparatus and endoplasmic reticulum, and they also appear to be present in the nuclear membrane (Conrad et al., 1993; Oetke et al., 2000) .
Studies with low-risk HPV6 provided the ®rst evidence that an HPV E5 protein had transforming activity in mammalian cells. These experiments showed that the HPV6 E5 protein conferred anchorage independent growth to established murine ®broblasts (Chen and Mounts, 1990) . It was soon reported that the HPV16 E5 protein caused anchorage independence, more ecient growth in low serum, and tumorigenic transformation of murine ®broblasts and epidermal keratinocytes (Leechanachai et al., 1992; Leptak et al., 1991; Pim et al., 1992) . In addition, the HPV16 E5 protein cooperates with the HPV16 E7 protein in inducing proliferation of primary rodent cells, and acute expression of the HPV16 E5 protein stimulates cellular DNA synthesis in primary human keratinocytes (Bouvard et al., 1994; Faulkner and Banks, 1995; Straight et al., 1993; Venuti et al., 1998) . E5 mutations in full-length HPV16 genomic DNA also inhibit immortalization of keratinocytes, but it is not clear if the E5 protein plays a direct role in immortalization (Stoppler et al., 1996) . Transforming activity of additional E5 proteins has been demonstrated in various cell types and assays (Ghai et al., 1996; Rho et al., 1996) .
Oncogene Mechanisms of cell transformation by papillomavirus E5 proteins D DiMaio and D Mattoon
HPV E5 protein and the epidermal growth factor receptor pathway Several lines of evidence suggest that receptor tyrosine kinase signaling plays an important role in transformation by the HPV16 E5 protein. However, unlike the case with BPV E5 protein, most reports implicate the epidermal growth factor (EGF) receptor, rather than the PDGF b receptor, as being involved in HPV E5 transformation. This dierence is consistent with the tissue tropism of the HPVs, which infect exclusively epithelial cells, a cell type rich in EGF receptors but thought to be devoid of PDGF receptors. In contrast, BPV also infects ®broblasts and other mesenchymal cells that express abundant PDGF b receptor.
Pim et al. reported that the HPV16 E5 protein induced anchorage independent growth in cells lacking endogenous EGF receptor only when the viral gene was co-expressed with the EGF receptor gene, and colony formation was enhanced by treatment with EGF but not PDGF (Pim et al., 1992) . Transformed cells also display evidence of heightened sensitivity to growth factor treatment. Cells expressing HPV16 E5 exhibit a more robust response to growth factor or phorbol ester treatment, as assessed by the level of transcription of early response genes such as c-fos and c-jun (Bouvard et al., 1994; Crusius et al., 1997; Leechanachai et al., 1992 , Pim et al., 1992 . The mitogenic eect of the HPV16 E5 protein on keratinocytes is potentiated by EGF treatment, as is the ability of this protein to cooperate with the HPV E7 protein. Cells expressing HPV16 E5 and related E5 proteins also display sustained activation of the ras/ mitogen-activated protein (MAP) kinase cascade in response to EGF and enhanced activation of protein kinase C following phorbol ester treatment (Crusius et al., 1997; Ghai et al., 1996; Gu and Matlashewski, 1995) .
In contrast to the ligand-independent activation of the PDGF b receptor caused by the BPV E5 protein, expression of the HPV16 E5 protein primarily aects the metabolism of the EGF receptor. For example, monolayer cultures of human keratinocytes expressing the HPV16 E5 protein display elevated levels of cell surface EGF receptors, apparently as a result of reduced ligand-induced degradation of the receptor in endosomes (Straight et al., 1993 (Straight et al., , 1995 . This is accompanied by increased recycling of the EGF receptor to the cell surface and elevated ligand-induced tyrosine phosphorylation of the receptor (Crusius et al., 1997; Straight et al., 1993) . HPV16 E5 expression also increased EGF receptor expression and receptor activation in stratifying raft cultures of human keratinocytes (Tomakidi et al., 2000) . Thus, the primary eect of the HPV E5 protein may be not to activate the receptor directly, but rather to sensitize cells so that they are more responsive to EGF. However, interactions with the EGF receptor do not appear to account for all the eects of the HPV16 E5 protein on cellular signal transduction pathways (Crusius et al., 1999) . Keratinocytes expressing the HPV-16 E5 protein display increased DNA synthesis and serum-free proliferation in response to endothelin-1, suggesting that the viral protein also enhances signaling via the G protein-coupled endothelin receptor (Venuti et al., 1998) . This eect does not appear to involve increased levels of endothelin receptor. HPV E5 proteins may also contribute to cell transformation by repressing expression of the cyclin-dependent kinase inhibitor, p21 WAF1/sdi1/cip1 . The HPV-16 E5 protein and various trans-membrane proteins, including the EGF receptor, can undergo complex formation when both proteins are overexpressed (Hwang et al., 1995) . However, this binding has not been observed in all studies (Conrad et al., 1994) . Thus, the biochemical basis of HPV E5-induced transformation and modulation of EGF receptor is unclear although, as noted below, interaction with the V-ATPase has been implicated.
HPV E5 and 16 kDa V-ATPase
The HPV6 and 16 E5 proteins physically associate with the 16 kDa subunit of the vacuolar ATPase in mammalian cells and yeast (Conrad et al., 1993) , but the functional consequences of this association have not been well established. Acidi®cation of endosomes is inhibited in mammalian cells expressing the HPV16 E5 protein, an eect that may be mediated by binding of the viral protein to the V-ATPase subunit (Straight et al., 1995) . Failure to acidify endosomes may be responsible for the inhibition of EGF receptor degradation, thereby allowing increased receptor recycling to the membrane (Figure 3) (Straight et al., 1993; Yoshimori et al., 1991) . However, a recent report suggests that HPV16 E5 aects endocytic tracking rather than endosome acidi®cation (Thomsen et al., 2000) . Gap junction-mediated cell-cell communication is also inhibited in keratinocytes expressing the HPV16 E5 protein (Oelze et al., 1995) . This eect may render transformed cells insensitive to growth inhibitory signals emanating from neighboring cells. The association between the E5 protein and the V-ATPase may be responsible for impaired cell-cell communication, because the V-ATPase subunit appears to be a component of gap junctions at the plasma membrane. Finally, the E5 protein/V-ATPase interaction may be responsible for the reduced motility displayed by mouse ®broblasts expressing the E5 protein (Thomsen et al., 1999) , since a similar eect is elicited by ba®lomycin A, which inhibits V-ATPase function (Yoshimori et al., 1991) .
Limited mutational analysis of HPV E5 proteins demonstrated that the interaction with the V-ATPase is mediated by the central hydrophobic region of the viral proteins, and that some E5 mutants able to bind the VATPase subunit do not impair V-ATPase function or enhance EGF receptor signaling (Adam et al., 2000; Rodriguez et al., 2000) . Similarly, HPV-11 E5 mutants defective for inducing anchorage independent growth in NIH3T3 cells retain the ability to bind to the 16 kDa protein . Complex formation between the V-ATPase and the HPV-16 E5 protein in Saccharomyces cerevisiae results in impaired acidi®ca-tion of vacuoles and a defect in cell growth (Briggs et al., 2001) . Further studies in yeast suggest that expression of the E5 proteins results in disruption of the multi-subunit V-ATPase complex (Adam et al., 2000; Briggs et al., 2001) .
Conclusions
There is now substantial evidence implicating papillomavirus E5 proteins in cell transformation. These proteins appear to act via receptor tyrosine kinase signaling pathways, perhaps in conjunction with the vacuolar ATPase. The interaction of BPV E5 protein and the PDGF b receptor de®nes a novel mechanism of DNA virus transformation. Analysis of this interaction has revealed new features of growth factor receptor signaling, for example that receptor tyrosine kinases can be activated in a ligand-independent fashion by proteins that do not resemble their normal ligands. Interactions between the BPV E5 protein and the transmembrane and juxtamembrane domains of the PDGF b receptor bridge two molecules of the receptor, resulting in receptor dimerization and activation. This model suggests that other short transmembrane proteins can be used to activate or inhibit a variety of growth factor receptors and other membrane proteins. Such proteins may have novel or useful properties, and they may also help de®ne the rules that govern the association of transmembrane domains. The biochemical basis for the eects of HPV E5 protein on EGF receptor function and cell phenotype have not been fully elucidated, and much work remains to be done to determine the mechanism of HPV E5-induced transformation of mammalian cells. Studies on HPV E5 proteins may also have bearing on our understanding of the cancers caused by HPV infection. The high-risk human papillomaviruses play a causative role in cervical neoplasia. Continued expression of the HPV E6 and E7 oncogenes is required to maintain the transformed phenotype of cancer cells, but little is known about the role of additional viral genes in human carcinogenesis. Expression of the E5 gene of the high-risk HPV types is often extinguished by integration of the viral genome during the progression to cervical cancer, so if the HPV E5 proteins play a role in carcinogenesis, they must act at an early stage during carcinogenic progression. Indeed, cervical carcinoma cells often express elevated EGF receptor (Maruo et al., 1992; Tervahauta et al., 1994) , a ®nding which mirrors the eect of the HPV E5 protein on cultured keratinocytes. The HPV E5 proteins may thus represent novel viral targets for therapeutic intervention. Indeed, immunization with an adenovirus vector expressing Figure 3 Model for the eect of the HPV16 E5 protein on EGF receptor recycling. In normal cells, activated EGF receptor is internalized and degraded in endosomes, thereby attenuating signaling. The vacuolar ATPase maintains the low pH required for receptor degradation. In E5-transformed cells, the E5 protein binds directly to the vacuolar ATPase and inhibits its activity. This impairs endosome acidi®cation and EGF receptor degradation, resulting in increased recycling of the receptor to the cell surface and enhanced receptor signaling HPV16 E5 can elicit cytotoxic T lymphocytes that can inhibit the growth of murine tumor cells engineered to express the viral protein (Liu et al., 2000) . Further study of the papillomavirus E5 proteins will continue to shed light on viral transformation and replication, cellular signal transduction and organelle function, carcinogenesis, and the assembly of transmembrane protein complexes.
